HS-20093

Generic Name: HS-20093

Clinical Trials

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors
Colorectal Cancer
Non-Small Cell Lung Cancer

Interventions: Drug: HS-10370
Drug: HS-20117
Drug: Adebrelimab
Drug: Capecitabine
Drug: HS-20093
Drug: Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan
Drug: Oxaliplatin
Drug: platinum (cisplatin or carboplatin)

First Posted Date: 2025-05-09

Last Posted Date: 2025-05-09

Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Target Recruit Count: 762

Registration Number: NCT06963502

Locations: 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
🇨🇳
Sun Yat-sen University Cancer Center, Shanghai, China

Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

Phase 3

Not yet recruiting

Conditions: Osteosarcoma

Interventions: Drug: HS-20093
Drug: Gemcitabine combined with docetaxel

First Posted Date: 2025-04-20

Last Posted Date: 2025-04-20

Lead Sponsor: Hansoh BioMedical R&D Company

Target Recruit Count: 117

Registration Number: NCT06935409

Locations: 🇨🇳
Beijing Jishuitan Hospital affiliated to Capital Medical University, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, China

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

Phase 1

Not yet recruiting

Conditions: Gastrointestinal Neoplasms

Interventions: Biological: GSK5764227

First Posted Date: 2025-03-19

Last Posted Date: 2025-04-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 120

Registration Number: NCT06885034

ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

Phase 1

Recruiting

Conditions: Metastatic Colorectal Cancer (CRC)

Interventions: Drug: HS-20093
Drug: Bevacizumab
Drug: 5-FU
Drug: Capecitabine
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2025-02-13

Last Posted Date: 2025-02-13

Lead Sponsor: Hansoh BioMedical R&D Company

Target Recruit Count: 560

Registration Number: NCT06825624

Locations: 🇨🇳
The Second Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, China

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

Phase 1

Not yet recruiting

Conditions: Osteosarcoma
Soft Tissue Sarcoma (STS)

Interventions: Drug: HS-20093
Drug: Anlotinib
Drug: Epirubicin
Drug: Adebrelimab

First Posted Date: 2024-11-21

Last Posted Date: 2024-11-21

Lead Sponsor: Hansoh BioMedical R&D Company

Target Recruit Count: 448

Registration Number: NCT06699576

A Study of GSK5764227 in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Neoplasms

Interventions: Biological: GSK5764227
Drug: Cisplatin
Drug: Carboplatin
Biological: Atezolizumab
Biological: Pembrolizumab
Biological: Durvalumab
Biological: Cetuximab
Biological: Bevacizumab

First Posted Date: 2024-08-13

Last Posted Date: 2025-03-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 281

Registration Number: NCT06551142

Locations: 🇬🇧
GSK Investigational Site, Edinburgh, United Kingdom

A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer

Phase 3

Not yet recruiting

Conditions: Limited-stage Small-cell Lung Cancer

Interventions: Drug: HS-20093

First Posted Date: 2024-07-30

Last Posted Date: 2024-07-30

Lead Sponsor: Hansoh BioMedical R&D Company

Target Recruit Count: 406

Registration Number: NCT06526624

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Small Cell Lung Cancer

Interventions: Drug: HS-20093
Drug: Topotecan

First Posted Date: 2024-07-12

Last Posted Date: 2024-10-16

Lead Sponsor: Hansoh BioMedical R&D Company

Target Recruit Count: 460

Registration Number: NCT06498479

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 6 locations

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: HS-20093
Drug: Adebrelimab
Drug: Cetuximab
Drug: Enzalutamide
Drug: Cisplatin/ Carboplatin

First Posted Date: 2024-03-27

Last Posted Date: 2024-07-18

Lead Sponsor: Hansoh BioMedical R&D Company

Target Recruit Count: 610

Registration Number: NCT06332170

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

Phase 2

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: HS-20093

First Posted Date: 2023-11-01

Last Posted Date: 2024-12-02

Lead Sponsor: Hansoh BioMedical R&D Company

Target Recruit Count: 220

Registration Number: NCT06112704

Locations: 🇨🇳
Jiangyin People's Hospital, Wuxi, Jiangsu, China
🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳
Fujian Provincial Tumor Hospital, Fujian, Fujian, China

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy